Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Drug Metab Pharmacokinet ; 55: 100492, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38609777

RESUMO

A ligand-accessible space in the CYP2C8 active site was reconstituted as a fused grid-based Template∗ with the use of structural data of the ligands. An evaluation system of CYP2C8-mediated metabolism has been developed on Template with the introduction of the idea of Trigger-residue initiated ligand-movement and fastening. Reciprocal comparison of the data of simulation on Template with experimental results suggested a unified way of the interaction of CYP2C8 and its ligands through the simultaneous plural-contact with Rear-wall of Template. CYP2C8 was expected to have a room for ligands between vertically standing parallel walls termed Facial-wall and Rear-wall. Both the walls were separated by a distance corresponding to 1.5-Ring (grid) diameter size, which was termed Width-gauge. The ligand sittings were stabilized through contacts with Facial-wall and the left-side borders of Template including specific Position 29, left-side border of Rings I/J, or Left-end, after Trigger-residue initiated ligand-movement. Trigger-residue movement is suggested to force ligands to stay firmly in the active site and then to initiate CYP2C8 reactions. Simulation experiments for over 350 reactions of CYP2C8 ligands supported the system established.


Assuntos
Citocromo P-450 CYP2C8 , Ligantes , Domínio Catalítico
2.
Drug Metab Pharmacokinet ; 48: 100481, 2023 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-36813636

RESUMO

A ligand-accessible space in the CYP2C19 active site was reconstituted as a fused grid-based Template with the use of structural data of the ligands. An evaluation system of CYP2C19-mediated metabolism has been developed on Template with the introduction of the idea of Trigger-residue initiated ligand-movement and fastening. Reciprocal comparison of the data of simulation on Template with experimental results suggested a unified way of the interaction of CYP2C19 and its ligands through the simultaneous plural-contact with Rear-wall of Template. CYP2C19 was expected to have a room for ligands between vertically standing parallel walls termed Facial-wall and Rear-wall, which were separated by a distance corresponding to 1.5-Ring (grid) diameter size. The ligand sittings were stabilized through contacts with Facial-wall and the left-side borders of Template including specific Position 29 or Left-end after Trigger-residue initiated ligand-movement. Trigger-residue movement is suggested to force ligands to stay firmly in the active site and then to initiate CYP2C19 reactions. Simulation experiments for over 450 reactions of CYP2C19 ligands supported the system established.


Assuntos
Ligantes , Citocromo P-450 CYP2C19 , Domínio Catalítico , Simulação por Computador
3.
Drug Metab Pharmacokinet ; 45: 100451, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35797783

RESUMO

A ligand-accessible space in the CYP2C9 active site was reconstituted as a fused grid-based Template with the use of structural data of the ligands. CYP2C9 Template generated has been developed as an evaluation system of CYP2C9 metabolism with the introduction of the idea of Trigger-residue initiated ligand-movement and fastening. Reciprocal comparison of the data of simulation on Template with experimental results suggested a unified way of the interaction of CYP2C9 and its ligands through the simultaneous plural-contact with Rear-wall of Template. CYP2C9 was expected to have a room for ligands between vertically standing parallel walls termed Facial-wall and Rear-wall. Both the walls were separated by a distance corresponding to 1.5-Ring (grid) diameter size, which was termed as Width-gauge. The results indicate that ligand sittings are stabilized through contacts with Facial-wall and the left-side border of Template including specific Position 29 or Left-end after Trigger-residue movement. In addition, Trigger-residue movement is suggested to force ligands to stay firmly in the active site and then initiate CYP2C9 reactions. Simulation experiments for over 500 reactions of CYP2C9 ligands supported the system established. Possible modes of enhanced catalyzes in bi-molecule bindings are also discussed.


Assuntos
Ligantes , Domínio Catalítico , Citocromo P-450 CYP2C9/genética
4.
Aquat Toxicol ; 233: 105792, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33662877

RESUMO

Although anticoagulant rodenticides (ARs) are effectively used for the control of invasive rodents, nontarget species are also frequently exposed to ARs and secondary poisonings occur widely. However, little data is available on the effects of ARs, especially on marine organisms. To evaluate the effects of ARs on marine wildlife, we chose green sea turtles (Chelonia mydas), which are one of the most common marine organisms around the Ogasawara islands, as our primary study species. The sensitivity of these turtles to ARs was assessed using both in vivo and in vitro approaches. We administered 4 mg/kg of warfarin sodium either orally or intravenously to juvenile green sea turtles. The turtles exhibited slow pharmacokinetics, and prolongation of prothrombin time (PT) was observed only with intravenous warfarin administration. We also conducted an in vitro investigation using liver microsomes from green sea turtles, and two other turtle species (softshell turtle and red-eared slider) and rats. The cytochrome P450 metabolic activity in the liver of green sea turtles was lower than in rats. Additionally, vitamin K epoxide reductase (VKOR), which is the target enzyme of ARs, was inhibited by warfarin in the turtles at lower concentration levels than in rats. These data indicate that turtles may be more sensitive to ARs than rats. We expect that these findings will be helpful for sea turtle conservation following accidental AR-broadcast incidents.


Assuntos
Anticoagulantes/toxicidade , Erros Inatos do Metabolismo/sangue , Rodenticidas/toxicidade , Tartarugas/sangue , Poluentes Químicos da Água/toxicidade , Animais , Resistência a Medicamentos , Ilhas , Fígado/efeitos dos fármacos , Fígado/metabolismo , Tempo de Protrombina , Ratos , Medição de Risco , Tartarugas/metabolismo
5.
Drug Metab Pharmacokinet ; 31(5): 363-384, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27665699

RESUMO

This prediction system is based on placements of CYP1A2-substrates on a hexagonal-grid template in a way following the rule generated from the relationship of the substrate-structure and selective-area uses on the template, and also the rule for a triggering-event to initiate the catalytic reactions. Clear relationship found between the placements and preferred-order of regioselective reactions from the comparison of experimental data of polyaromatic hydrocarbon (PAH)-substrates was implemented in this system. The template generated is consisted of two flat-shape regions (Thin- and Thick-Areas) and Site of Oxidation. The latter is located at an overlapping region of Thin- and Thick-Areas and has a shape of cubic-like block. Thin-Area and Thick-Area are not on the same plane, and bend slightly at their overlapping parts. Two Entrances and two Gatekeepers are situated each near the top and middle bottleneck-parts of Thin-Area and Thick-Area to restrict the substrate entry. A procedure of stepwise movement of substrates resided on Thick-Area is introduced to define the regioselectivity. A specific part (termed Trigger-Region) showing high placement rates was found at a region away from Site of Oxidation on the template, assuming that substrate-sittings at Trigger-Region are essential for the initiation of catalytic reactions. These observations lead us an idea of simultaneous bi-molecule placement to fulfill both the essential sitting at Trigger-Region and regioselectivity of metabolisms, although a uni-molecule sitting co-covering Trigger-Region is also possible to contribute for the metabolite formation. Substrates of CYP1A2 are verified from distinct points including selective use of Thin-Area, Trigger-molecule Harboring Area, dual access routs, Facial-side Movement as well as their sizes. In addition, inhibitory actions as well region/stereo selective oxid/reductions of both PAH and non-PAH molecules are verified with their supposable interaction mechanisms in this prediction system.


Assuntos
Citocromo P-450 CYP1A2/metabolismo , Sítios de Ligação/fisiologia , Catálise , Humanos , Modelos Moleculares , Oxirredução , Especificidade por Substrato/fisiologia
6.
J Pharmacol Sci ; 129(1): 18-25, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26320673

RESUMO

Recent studies have shown that rebamipide, which suppresses reactive oxygen species, prevents chemoradiotherapy-induced oral mucositis in patients with head and neck cancers. However, anticancer action of radiotherapy and chemotherapy is believed to be partially associated with generation of reactive oxygen species. The aim of this study was to determine whether rebamipide interferes with the antitumor action of radiotherapy and chemotherapy. The effect of rebamipide on tumor cell growth was investigated using a human oral squamous carcinoma cell line, HSC-2, in vitro and in vivo. Rebamipide showed no significant effect on cell or tumor growth in HSC-2 tumor-bearing nude mice. Influences of rebamipide on the antitumor action of radiotherapy and of chemotherapy with cisplatin or docetaxel were investigated using the same animal model. In radiotherapy, the tumor was treated with 2.5 Gy of X-rays for 5 days, and rebamipide (300 mg/kg p.o.) was administered during irradiation periods. In chemotherapy, tumor-bearing mice were treated once with cisplatin (8 mg/kg, i.v.) or docetaxel (15 mg/kg i.v.) and rebamipide (300 mg/kg p.o.) was administered for 5 days following the antitumor drug treatment. Rebamipide did not interfere with the antitumor action of radiotherapy and chemotherapy.


Assuntos
Alanina/análogos & derivados , Antineoplásicos/uso terapêutico , Antioxidantes/farmacologia , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/radioterapia , Cisplatino/uso terapêutico , Quinolonas/farmacologia , Taxoides/uso terapêutico , Alanina/administração & dosagem , Alanina/farmacologia , Alanina/uso terapêutico , Animais , Antineoplásicos/efeitos adversos , Antioxidantes/administração & dosagem , Antioxidantes/uso terapêutico , Linhagem Celular Tumoral , Cisplatino/efeitos adversos , Modelos Animais de Doenças , Docetaxel , Interações Medicamentosas , Feminino , Humanos , Camundongos Endogâmicos BALB C , Camundongos Nus , Transplante de Neoplasias , Quinolonas/administração & dosagem , Quinolonas/uso terapêutico , Radioterapia/efeitos adversos , Estomatite/etiologia , Estomatite/prevenção & controle , Taxoides/efeitos adversos
7.
Biol Pharm Bull ; 38(9): 1425-9, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26094899

RESUMO

The direct inhibitory potential of twenty five anti-tuberculosis drugs on eight CYP-specific reactions in human liver microsomes was investigated to predict in vivo drug-drug interactions (DDIs) from in vitro data. Rifampicin, rifabutin, and thioacetazone inhibited one CYP reaction. Isoniazid and clofazimine had inhibitory effects on four CYP reactions, and rifapentine, ethionamide, and prothionamide widely inhibited CYP reactions. Based on the inhibition constant (Ki) and the therapeutic total inhibitor concentrations [I]max of eight drugs in human plasma, [I]max/Ki values were calculated to evaluate clinical DDIs. The [I]max/Ki values were 0.20 or less for rifampicin, rifabutin, and thioacetazone; 0.15-2.0 for isoniazid; 0.14-1.5 for rifapentine; 0.29-1.4 for ethionamide; 0.41-2.2 for prothionamide; and 0.12-6.3 for clofazimine. The highest [I]max/Ki values were 2.0 for isoniazid on CYP3A4 [testosterone (T)]; 1.5 for rifapentine on CYP3A4 [midazolam (M)]; 1.4 for ethionamide on CYP2C8; 2.2, 1.8, and 1.3 for prothionamide on CYP2B6, CYP2C19, and CYP2C8, respectively; and 6.3 and 5.7 for clofazimine on CYP3A4 (M) and CYP3A4 (T), respectively. These drugs with high [I]max/Ki values lead to clinical DDIs. Considering the drug regimens for tuberculosis (TB) and co-infection with TB and human immunodeficiency virus, the inhibitory potential for CYP3A4 and CYP2B6 is particularly important. These results suggest that clofazimine and prothionamide are likely to cause clinically relevant DDIs when co-administered with products metabolized by CYP3A4 and CYP2B6, respectively. Isoniazid and rifapentine may cause DDIs with drugs metabolized by CYP3A4.


Assuntos
Antituberculosos/farmacologia , Inibidores das Enzimas do Citocromo P-450/farmacologia , Microssomos Hepáticos/efeitos dos fármacos , Sistema Enzimático do Citocromo P-450/metabolismo , Interações Medicamentosas , Humanos , Microssomos Hepáticos/metabolismo
8.
Xenobiotica ; 45(4): 353-60, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25815637

RESUMO

1. Chlorzoxazone (CLZ) is currently being used as a marker substrate in vitro/vivo studies to quantify cytochrome P450 2E1 (CYP2E1) activity in humans. Although in CLZ 6-hydroxylation several CYPs are responsible, previous studies have presented the monophasicity of the reaction in human liver microsomes (HLMs). Furthermore, the Km values of CYP2E1 for the 6-hydroxylation in HLMs were reported to be lower than those of its recombinant enzymes. 2. This study aimed to provide the comprehensive Km values for the CLZ 6-hydroxylation in HLMs using CYP antibodies. The Eadie-Hofstee plots revealed a biphasic profile and indicate that the reaction was mainly mediated by CYP1A2 as well as CYP2E1. The formation of 6-hydroxychlorzoxazone was more specific for CYP2E1 activity at higher substrate concentration in HLMs. 3. Moreover, KOH as a vehicle for substrate or sucrose included in HLMs preparation had some effect on the activity of CLZ 6-hydroxylase. These constituents seemed to be casually related to the apparent monophasic kinetics and variability in Km values for the CLZ 6-hydroxylation in HLMs. 4. The Km of CYP1A2 and CYP2E1 in HLMs was 3.8 µmol/L and 410 µmol/L, respectively, and the value of CYP2E1 was close to that of recombinant CYP2E1.


Assuntos
Clorzoxazona/análogos & derivados , Citocromo P-450 CYP1A2/metabolismo , Citocromo P-450 CYP2E1/metabolismo , Microssomos Hepáticos/efeitos dos fármacos , Clorzoxazona/farmacocinética , Cromatografia Líquida , Humanos , Hidroxilação , Microssomos Hepáticos/metabolismo , Proteínas Recombinantes/metabolismo , Espectrometria de Massas em Tandem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...